Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04776252 | Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) | PHASE3 | ACTIVE NOT_RECRUITING | 2,000 | — | — | Sep 15, 2021 | May 29, 2029 | Dec 23, 2025 | 93 | United States, Australia +14 |
Percentage of participants with serious adverse events (SAEs)
Percentage of participants who discontinued study treatment due to an AE.
| Arm | Type | Description |
|---|---|---|
| MK-8591A | EXPERIMENTAL | Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks. |
| Name | Type | Description |
|---|---|---|
| MK-8591A | DRUG | FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks |
Inclusion Criteria: * Is currently receiving DOR 100 mg/ISL 0.75 mg adult FDC tablet in an MSD-sponsored clinical study and has completed the last treatment visit. * Is considered by the investigator to have derived clinical benefit from receiving DOR/ISL and for whom further treatment with DOR/ISL...